NCT00092534 2025-08-01
FUTURE II
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
9 trialsNCT03493542 2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01492582 2021-10-27
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
University of Alabama at Birmingham
Phase 2 Completed
NCT01245764 2018-11-14
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00090285 2018-08-23
V501-020
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00411749 2017-04-21
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00496626 2017-04-17
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00524745 2017-04-14
Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
PATH
Phase NA Completed
NCT00092495 2015-01-13
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
Merck Sharp & Dohme LLC
Phase 3 Completed